This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Bupropion-Amantadine-Associated Neurotoxicity

Brian Trappler and Augusto M. Miyashiro

Published: June 30, 2000

Article Abstract

Letter to the Editor

Sir: The antidepressant drug bupropion is a substituted chloropropiophenone with a structure reminiscent of stimulant and anorectic drugs such as diethylpropion. It exerts both a stimulant profile, as shown by increases in motor activity, and an antidepressant profile. Some data show that bupropion increases dopamine concentration in the mesolimbic system involved in the neural circuitry of reward.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: Psychopharmacology

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...